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thank Dr. Kapoor for his interest in my review (1) and entirely
gree that improvement in symptoms often accompanies surgery
or secondary mitral regurgitation (MR). The remaining question
s: how does surgery do so? Three potential mechanisms come to
ind. First, there is the placebo effect of surgery. Over 5 decades
go implantation of the internal mammary artery directly into the
yocardium and/or ligation of the internal mammary arteries
educed the symptoms of myocardial ischemia, whereas more
ecently sham knee surgery had an equal outcome to arthroscopic
avage and/or debridement (2–4), demonstrating the power of
he placebo. It seems highly unlikely that sham mitral surgery
ill ever be performed to test the placebo hypothesis, but it
hould be kept in mind. A second mechanism by which mitral
alve surgery for secondary MR might be helpful is the one that
eems most obvious, by elimination of the MR. The Acorn trial
ound substantial reverse remodeling in the mitral valve repair
rm of the trial supporting this mechanism (5). However,
lmost all mitral repairs also alter the mitral annulus, and many
ings now attempt to alter ventricular geometry, raising this as
third possibility (6). Thus it is unknown whether it is the
nnuloplasty or correction of the MR or both that is beneficial.
t would have been enlightening if the Acorn trial had an
corn-only arm. Quite possibly it would have been as effective
s the annuloplasty.
We have much to learn about the role of secondary MR and its
orrection in the treatment of heart failure. It seems so simple to
ay “it’s there, it’s bad, let’s fix it,” and that might be the correctpproach, but it also might not be. Let’s not let the genie out of the
ottle until we have better proof.
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